MedWatch - April 2011 Drug Safety Labeling Changes: 43 products with 22 changes to BW, Contraindications or Warnings

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: MedWatch - April 2011 Drug Safety Labeling Changes: 43 products with 22 changes to BW, Contraindications or Warnings
MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

The MedWatch April 2011 Safety Labeling Changes posting includes 43 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE.

The "Summary Page" provides a listing of drug names and safety labeling sections revised:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm253470.htm

Clicking on a drug product name in the Summary View will take you to the "detailed view" page, which identifies safety labeling sections and subsections revised, along with a brief summary of new or modified safety information.

The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and WARNINGS sections:    
Aplenzin (bupropion hydrobromide) Extended-Release Tablets
Fosrenal (lanthanum carbonate) Chewable Tablets
Advil (ibuprofen) Infants oral suspension
Advil (ibuprofen) tablets
Advil Liqui-Gels (ibuprofen) capsules
Advil PM (ibuprofen 200 mg/diphenhydramine citrate 38 mg) tablets
Aleve (naproxen sodium) tablets
Chorionic Gonadotropin for Injection
Combivent (ipratropium bromide and albuterol sulfate) Aerosol
Cyanokit (hydroxocobalamin for Injection)
Demerol (meperidine hydrochloride)
Eligard (leuprolide acetate) injectable suspension
Fuzeon (enfuvirtide) for Injection
Gleevec (imatinib mesylate) Tablets
Invega (paliperidone) extended-release tablets
Janumet (sitagliptin/metformin hydrochloride) Tablets
Januvia (sitagliptin) Tablets
Lysteda (tranexamic acid) Tablets
Novarel (chorionic gonadotropin for Injection, USP)
Omnitrope (somatropin [rDNA origin] injection)
Pregnyl (chorionic gonadotropin for Injection, USP)
Zemplar (Paricalcitol) Injection

Tell us what you think:  http://survey.foreseeresults.com/survey/display?cid=d509U9xg0gZVxkMRcoMsQg==&sid=link&cpp[date]=5-16-2011 2200&cpp[type]=info


You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm

Follow MedWatch on Twitter twitter

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

FDA HHS

U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux